TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
MALVERN, Pa., Feb. 23, 2017 -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biotechnology company, will release its fourth quarter financial results before the market opens on March 15, 2017
Management will conduct a conference call at 8:00 a.m. ET that day to discuss the Company’s financial results and provide a general business update. The conference will be webcast live over the Internet and can be accessed by logging on to the “Investors” section of the Aclaris Therapeutics website, www.aclaristx.com, prior to the event. A replay of the webcast will be archived on the Company’s website for 30 days following the call.
To participate on the live call, please dial (844) 776-7782 (domestic) or (661) 378-9535 (international), and reference conference ID 62366728 prior to the start of the call.
About Aclaris
Aclaris Therapeutics, Inc. is a clinical-stage dermatologist-led biotechnology company focused on identifying, developing and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology. Aclaris is based in Malvern, Pennsylvania and more information can be found by visiting the Aclaris website at www.aclaristx.com.
Contact: Aclaris Contact Michael Tung, M.D. Investor Relations 484-329-2140 [email protected] Media Contact Mariann Caprino TogoRun 917-242-1087 [email protected]
